-
Viatris Receives U.S. FDA Approval for Ryzumvi for the Treatment of Presbyopia
NASDAQ: $VTRS PITTSBURGH, Oct. 16, 2026 /PRNewswire/ — Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved Ryzumvi (phentolamine ophthalmic solution 0.75%) for the treatment of… Source: Read More
-
Viatris Advances Contraceptive Care: New Data on Weekly Low-Dose Patch to be Presented at ACOG 2026
NASDAQ: $VTRS As we approach the 2026 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting in Washington, D.C., the medical community is turning its attention toward significant advancements in reproductive health. Viatris Inc. recently announced it will present six new abstracts regarding its investigational low-dose estrogen combined hormonal contraceptive (CHC) weekly…
-
Viatris Announces Q4 and Full-Year 2025 Financial Results Date and Investor Event Schedule
NASDAQ: $VTRS Viatris Inc. has officially announced the schedule for reporting its financial outcomes for the fourth quarter and the entirety of the 2025 fiscal year. This important update for investors and stakeholders is set for release on Thursday, February 26, 2026. Following the release of the comprehensive financial figures, Viatris will host a conference…